CRISPR

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Diagram of the CRISPR prokaryotic antiviral defense mechanism.[1]

Clustered regularly interspaced short palindromic repeats (CRISPR, pronounced crisper[2]) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.[3]

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages,[4][5][6] and provides a form of acquired immunity. The Cas protein(s) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms.[3] CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.[7][note 1]

By delivering the Cas9 nuclease and appropriate guide RNAs into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added.[8][9][10] CRISPRs have been used in concert with specific endonuclease enzymes for genome editing and gene regulation in species throughout the tree of life.[11]

Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida.[12][13] Other such systems are thought to exist.[14]

CRISPR/C2c2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.[15]

The CRISPR interference technique has many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR for genome editing[16][17] was the AAAS's choice for breakthrough of the year in 2015.[18] Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.[19]

CRISPR
4qyz.jpg
Identifiers
Organism E.Coli
Symbol ?

History[edit]

The discovery of clustered DNA repeats began at three independent locations in three parts of the world. The first description of what would later be called CRISPR was from Osaka University researcher Yoshizumi Ishino in 1987, who accidentally cloned part of a CRISPR together with the iap gene, the target of interest. The organization of the repeats was unusual because repeated sequences are typically arranged consecutively along DNA. The function of the interrupted clustered repeats was not known at the time.[20][21] In 1993 researchers of Mycobacterium tuberculosis in the Netherlands published two articles about a repeat cluster in this bacterium that was named "direct repeat (DR)" region. These researchers recognized the diversity in the composition of repeat cluster spacers,[22] and this property was used to design a typing method that was named Spoligotyping which is still in use today.[23] At the same time, the later called CRISPR's were also observed in the archaeal organism Haloferax mediteranii and its function was studied by Mojica at the University of Alicante, Spain.[24] It lasted till 1997 when Ruud Jansen at the University of Utrecht, the Netherlands recognized the similar structure of the iap repeats of E. coli and the DR region of M. tuberculosis and employing the Patscan program designed by Ross Overbeek from Argonne National Laboratory USA, recognized the repeat cluster of H. mediteranii as a member of the CRISPR family. From that time on the two researchers (Jansen and Mojica) working on CRISPR were in contact. Using Patscan, numerous CRISPR's were recognized in the whole genomes of bacteria and archea that were published, indicating that CRISPR is a universal feature of prokaryotes. The wide spread dispersal of CRISPR among prokaryotes was presented at the Genomes 2000 meeting at the Institute Pasteur in Paris by Jansen (named SPacer Interspersed Direct Repeat (SPIDR)) and published by Mojica in the same year and named SRSR[25] A major addition to the understanding of CRISPR came with the observation that the repeat cluster was accompanied in the prokaryotic genomes by a set of homologous genes, the CRISPR associated or cas genes. Four cas genes (cas 1 to 4) were recognized and the Cas proteins showed helicase and nuclease motifs, suggesting a role of these proteins in the dynamic structure of the CRISPR loci.[26] In this publication the acronym CRISPR was coined as the universal name of this locus. However, the CRISPR function remained enigmatic and it took three more years for the next step was made in understanding CRISPR.

Simplified diagram of a CRISPR locus. The three major components of a CRISPR locus are shown: cas genes, a leader sequence, and a repeat-spacer array. Repeats are shown as gray boxes and spacers are colored bars. The arrangement of the three components is not always as shown.[1][3] In addition, several CRISPRs with similar sequences can be present in a single genome, only one of which is associated with cas genes.[7]

In 2005, three independent research groups showed that some CRISPR spacers are derived from phage DNA and extrachromosomal DNA such as plasmids.[27][28][29] In effect, the spacers are fragments of DNA gathered from viruses that previously tried to attack the cell. The source of the spacers was a sign that the CRISPR/cas system could have a role in adaptive immunity in bacteria.[1][30] All three studies proposing this idea were initially rejected by high-profile journals but were eventually published in other journals.[31]

Although researchers came to an understanding that CRISPR-Cas was involved in microbial immunity, the mechanism of how the spacers conferred immunity remained a mystery.[21] Koonin and colleagues proposed that spacers produce small RNA guides to target RNA transcribed from viral DNA, analogous to the RNA interference system used by eukaryotic cells.[21][32] Others hypothesized that CRISPR sequences directed Cas enzymes to degrade viral DNA.[21][29]

Experimental work by several groups revealed the basic mechanisms of CRISPR-Cas immunity. In 2007, Barrangou, Horvath, and other food industry scientists at Danisco provided the first experimental evidence that CRISPR was an adaptive immune system.[21] A CRISPR region in Streptococcus thermophilus acquired spacers from DNA of infecting bacteriophage. The researchers manipulated the resistance of S. thermophilus to phage by adding and deleting spacers whose sequence matched those found in the phages tested.[33][34] In 2008, Brouns and colleagues identified a complex of Cas protein that in E. coli cut the CRISPR RNA within the repeats into spacer-containing RNA molecules, which remained bound to the protein complex. In the same year, Marraffini and Sontheimer showed that a CRISPR sequence of Staphylococcus epidermidis targeted DNA and not RNA to prevent conjugation. This finding was at odds with the proposed RNA-interference-like mechanism of CRISPR-Cas immunity, although a CRISPR-Cas system that targets foreign RNA was later found in Pyrococcus furiosus.[21][33] A 2010 study provided direct evidence that CRISPR-Cas cuts both strands of phage and plasmid DNA in S. thermophilus.[35][36]

Cas9[edit]

Jennifer Doudna and Emmanuelle Charpentier studied a simpler CRISPR system from Streptococcus pyogenes that relies on the protein Cas9. The Cas9 endonuclease is a four-component system that includes two small RNA molecules.[37] In 2012, they re-engineered Cas9 endonuclease into a more manageable two-component system by fusing the two RNA molecules into a "single-guide RNA" that, when mixed with Cas9, could find and cut the DNA target specified by the guide RNA. By manipulating the nucleotide sequence of the guide RNA, the artificial Cas9 system could be programmed to target any sequence in DNA for cleavage.[38] This technological advance has fueled efforts to edit genomes with the re-engineered CRISPR-Cas9 system.[39]

Feng Zhang's and George Church's groups simultaneously described genome editing in human cell cultures using CRISPR-Cas9 systems for the first time.[21][40][41] It has since been used in a wide range of organisms, including baker's yeast (Saccharomyces cerevisiae),[42][43][44] zebrafish (D. rerio),[45] fruit flies (Drosophila melanogaster),[46] axolotl (A. mexicanum),[47] nematodes,(C. elegans),[48] plants,[49] mice,[50] monkeys[51] and human embryos.[52]

CRISPR has been modified to make programmable transcription factors that allow scientists to target and activate or silence specific genes.[53]

Libraries of tens of thousands of guide RNAs are available.[34]

Cpf1[edit]

In 2015, the nuclease Cpf1 was discovered in the CRISPR/Cpf1 system of the bacterium Francisella novicida.[12][13] Cpf1 showed several key differences to Cas9 including: causing a 'staggered' cut in double stranded DNA as opposed to the 'blunt' cut produced by Cas9, relying on a 'T rich' Protospacer adjacent motif (providing alternate targeting sites to Cas9) and requiring only a CRISPR RNA (crRNA) for successful targeting (with Cas9 requiring both crRNA and a transactivating crRNA (tracrRNA)).

Predecessors[edit]

In the early 2000s, researchers developed zinc finger nucleases, synthetic proteins whose DNA-binding domains enable them to create double-stranded breaks in DNA at specific points. In 2010, synthetic nucleases called TALENs provided an easier way to target a double-stranded break to a specific location on the DNA strand. Both zinc finger nucleases and TALENs require the creation of a custom protein for each targeted DNA sequence, which is a more difficult and time-consuming process than that for guide RNAs. CRISPRs are much easier to design because the process requires making only a short RNA sequence.[54]

Locus structure[edit]

Repeats and spacers[edit]

CRISPR repeats range in size from 24 to 48 base pairs.[55] They usually show some dyad symmetry, implying the formation of a secondary structure such as a hairpin, but are not truly palindromic.[56] Repeats are separated by spacers of similar length.[55] Some CRISPR spacer sequences exactly match sequences from plasmids and phages,[27][28][29] although some spacers match the prokaryote's genome (self-targeting spacers).[27][57] New spacers can be added rapidly as part of the immune response to phage infection.[58]

Cas genes and CRISPR subtypes[edit]

Small clusters of cas genes are often located next to CRISPR repeat-spacer arrays. Comparative genomics identified multiple cas genes; an initial analysis of 200 bacterial and archaeal genomes suggested as many as 45 cas gene families.[55]

The current classification groups CRISPR-Cas systems into two classes. Class 1 systems use a complex of multiple Cas proteins to degrade foreign nucleic acids. Class 2 systems use a single large Cas protein for the same purpose. Class 1 is divided into types I, III, and IV; class 2 is divided into types II and V. The five system types are divided into 16 subtypes. Each type and most subtypes are characterized by a "signature gene" found exclusively in the category. Classification is also based on the complement of cas genes that are present. Most CRISPR-Cas systems have a Cas1 protein. The phylogeny of Cas1 proteins generally agrees with the classification system.[59] Many organisms contain multiple CRISPR-Cas systems suggesting that they are compatible and may share components.[36][60] The sporadic distribution of the CRISPR/Cas subtypes suggests that the CRISPR/Cas system is subject to horizontal gene transfer during microbial evolution.

Signature genes and their putative functions for the major and minor CRISPR-cas types.
Class Cas type Signature gene Function Reference
1 I Cas3 Single-stranded DNA nuclease (HD domain) and ATP-dependent helicase [61][62]
IA Cas8a Subunit of the interference module. Important in targeting of invading DNA by recognizing the PAM sequence [63][64]
IB Cas8b
IC Cas8c
ID Cas10d contains a domain homologous to the palm domain of nucleic acid polymerases and nucleotide cyclases [65][66]
IE Cse1
IF Csy1 Not determined
IU
III Cas10 Homolog of Cas10d and Cse1 [66]
IIIA Csm2 Not Determined
IIIB Cmr5 Not Determined
IIIC
IIID
IV Csf1
IVA
IVB
2 II Cas9 Nucleases RuvC and HNH together produce DSBs, and separately can produce single-strand breaks. Ensures the acquisition of functional spacers during adaptation. [67][68]
IIA Csn2 Ring-shaped DNA-binding protein. Involved in primed adaptation in Type II CRISPR system. [69]
IIB Cas4 Not Determined
IIC Characterized by the absence of either Csn2 or Cas4 [70]
V Cpf1 Nuclease RuvC. Lacks HNH.

Mechanism[edit]

The stages of CRISPR immunity for each of the three major types of adaptive immunity. (1) Acquisition begins by recognition of invading DNA by Cas1 and Cas2 and cleavage of a protospacer. (2) The protospacer is ligated to the direct repeat adjacent to the leader sequence and (3) single strand extension repairs the CRISPR and duplicates the direct repeat. The crRNA processing and interference stages occur differently in each of the three major CRISPR systems. (4) The primary CRISPR transcript is cleaved by cas genes to produce crRNAs. (5) In type I systems Cas6e/Cas6f cleave at the junction of ssRNA and dsRNA formed by hairpin loops in the direct repeat. Type II systems use a trans-activating (tracr) RNA to form dsRNA, which is cleaved by Cas9 and RNaseIII. Type III systems use a Cas6 homolog that does not require hairpin loops in the direct repeat for cleavage. (6) In type II and type III systems secondary trimming is performed at either the 5’ or 3’ end to produce mature crRNAs. (7) Mature crRNAs associate with Cas proteins to form interference complexes. (8) In type I and type II systems, interactions between the protein and PAM sequence are required for degradation of invading DNA. Type III systems do not require a PAM for successful degradation and in type III-A systems basepairing occurs between the crRNA and mRNA rather than the DNA, targeted by type III-B systems.

CRISPR-Cas immunity is a natural process of bacteria and archaea. CRISPR-Cas prevents bacteriophage infection, conjugation, and natural transformation by degrading foreign nucleic acids that enter the cell.[33]

Spacer acquisition[edit]

When a microbe is invaded by a virus, the first stage of the immune response is to capture viral DNA and insert it into a CRISPR locus in the form of a spacer. Cas1 and Cas2 are found in all three types of CRISPR-Cas immune systems, which indicates that they are involved in spacer acquisition. Mutation studies confirmed this hypothesis, showing that removal of cas1 or cas2 stopped spacer acquisition, without affecting CRISPR immune response.[63][71][72][73][74]

Multiple Cas1 proteins have been characterised and their structures resolved.[75][76][77] Cas1 proteins have diverse amino acid sequences. However, their crystal structures are similar and all purified Cas1 proteins are metal-dependent nucleases/integrases that bind to DNA in a sequence-independent manner.[36] Representative Cas2 proteins have been characterised and possess either ssRNA-[78] or dsDNA-[79][80] specific endoribonuclease activity.

In the I-E system of E. coli Cas1 and Cas2 form a complex where a Cas2 dimer bridges two Cas1 dimers.[81] In this complex Cas2 performs a non-enzymatic scaffolding role,[81] binding double-stranded fragments of invading DNA, while Cas1 binds the single-stranded flanks of the DNA and catalyses their integration into CRISPR arrays.[82][83][84]

Protospacer adjacent motifs[edit]

Bioinformatic analysis of regions of phage genomes that were excised as spacers (termed protospacers) revealed that they were not randomly selected but instead were found adjacent to short (3 – 5 bp) DNA sequences termed protospacer adjacent motifs (PAM). Analysis of CRISPR-Cas systems from the three major divisions showed PAMs to be important for type I and type II, but not type III systems during acquisition.[29][85][86][87][88][89] In type I and type II systems, protospacers are excised at positions adjacent to a PAM sequence, with the other end of the spacer cut using a ruler mechanism, thus maintaining the regularity of the spacer size in the CRISPR array.[90][91] The conservation of the PAM sequence differs between CRISPR-Cas systems and appears to be evolutionarily linked to Cas1 and the leader sequence.[89][92]

New spacers are added to a CRISPR array in a directional manner,[27] occurring preferentially,[58][85][86][93][94] but not exclusively, adjacent[88][91] to the leader sequence. Analysis of the type I-E system from E. coli demonstrated that the first direct repeat, adjacent to the leader sequence is copied, with the newly acquired spacer inserted between the first and second direct repeats.[73][90]

The PAM sequence appears to be important during spacer insertion in type I-E systems. That sequence contains a strongly conserved final nucleotide (nt) adjacent to the first nt of the protospacer. This nt becomes the final base in the first direct repeat.[74][95][96] This suggests that the spacer acquisition machinery generates single-stranded overhangs in the second-to-last position of the direct repeat and in the PAM during spacer insertion. However, not all CRISPR-Cas systems appear to share this mechanism as PAMs in other organisms do not show the same level of conservation in the final position.[92] It is likely that in those systems, a blunt end is generated at the very end of the direct repeat and the protospacer during acquisition.

Insertion variants[edit]

Analysis of Sulfolobus solfataricus CRISPRs revealed further complexities to the canonical model of spacer insertion, as one of its six CRISPR loci inserted new spacers randomly throughout its CRISPR array, as opposed to inserting closest to the leader sequence.[91]

Multiple CRISPRs contain many spacers to the same phage. The mechanism that causes this phenomenon was elucidated in the type I-E system of E. coli. A significant enhancement in spacer acquisition was detected where spacers already target the phage, even mismatches to the protospacer. This ‘priming’ requires the Cas proteins involved in both acquisition and interference to interact with each other. Newly acquired spacers that result from the priming mechanism are always found on the same strand as the spacer that caused the priming.[74][95][96] This observation led to the hypothesis that the acquisition machinery slides along the foreign DNA after priming to find a new protospacer.[96]

Biogenesis[edit]

CRISPR-RNA (crRNA), which later guides the Cas nuclease to the target during the interference step, must be generated from the CRISPR sequence. The crRNA is initially transcribed as part of a single long transcript encompassing much of the CRISPR array.[3] This transcript is then cleaved by Cas proteins to form crRNAs. The mechanism to produce crRNAs differs among CRISPR-Cas systems. In type I-E and type I-F systems, the proteins Cas6e and Cas6f respectively, recognise stem-loops[97][98][99] created by the pairing of identical repeats which flank the crRNA.[56] These Cas proteins cleave the longer transcript at the edge of the paired region, leaving a single crRNA along with a small remnant of the paired repeat region.

Type III systems also use Cas6, however their repeats do not produce stem-loops. Cleavage instead occurs by the longer transcript wrapping around the Cas6 to allow cleavage just upstream of the repeat sequence.[100][101][102]

Type II systems lack the Cas6 gene and instead utilize RNaseIII for cleavage. Functional type II systems encode an extra small RNA that is complementary to the repeat sequence, known as a trans-activating crRNA (tracrRNA).[71] Transcription of the tracrRNA and the primary CRISPR transcript results in base pairing and the formation of dsRNA at the repeat sequence, which is subsequently targeted by RNaseIII to produce crRNAs. Unlike the other two systems the crRNA does not contain the full spacer but instead is truncated at one end.[67]

CrRNAs associate with Cas proteins to form ribonucleotide complexes that recognize foreign nucleic acids. CrRNAs show no preference between the coding and non-coding strands, which is indicative of an RNA-guided DNA-targeting system.[6][35][63][74][103][104][105] The type I-E complex (commonly referred to as Cascade) requires five Cas proteins bound to a single crRNA.[106][107]

Interference[edit]

During the interference stage in type I systems the PAM sequence is recognized on the crRNA-complementary strand and is required along with crRNA annealing. In type I systems correct base pairing between the crRNA and the protospacer signals a conformational change in Cascade that recruits Cas3 for DNA degradation.

Type II systems rely on a single multifunctional protein, Cas9, for the interference step.[67] Cas9 requires both the crRNA and the tracrRNA to function and cleaves DNA using its dual HNH and RuvC/RNaseH-like endonuclease domains. Basepairing between the PAM and the phage genome is also required in type II systems, however the PAM is recognized on the same strand as the crRNA (the opposite strand to type I systems).

Type III systems, like type I require six or seven Cas proteins binding to crRNAs.[108][109] The type III systems analysed from S. solfataricus and P. furiosus both target the mRNA of phages rather than phage DNA genome,[60][109] which may make these systems uniquely capable of targeting RNA-based phage genomes.[36]

The mechanism for distinguishing self from foreign DNA during interference is built into the crRNAs and is therefore likely common to all three systems. Throughout the distinctive maturation process of each major type, all crRNAs contain a spacer sequence and some portion of the repeat at one or both ends. It is the partial repeat sequence that prevents the CRISPR-Cas system from targeting the chromosome as base pairing beyond the spacer sequence signals self and prevents DNA cleavage.[110] RNA-guided CRISPR enzymes are classified as type V restriction enzymes.

CRISPR associated protein
PDB 1wj9 EBI.jpg
crystal structure of a crispr-associated protein from Thermus thermophilus
Identifiers
Symbol CRISPR_assoc
Pfam PF08798
Pfam clan CL0362
InterPro IPR010179
CDD cd09727
CRISPR associated protein Cas2
PDB 1zpw EBI.jpg
crystal structure of a hypothetical protein tt1823 from Thermus thermophilus
Identifiers
Symbol CRISPR_Cas2
Pfam PF09827
InterPro IPR019199
CDD cd09638
CRISPR-associated protein Cse1
Identifiers
Symbol CRISPR_Cse1
Pfam PF09481
InterPro IPR013381
CDD cd09729
CRISPR-associated protein Cse2
Identifiers
Symbol CRISPR_Cse2
Pfam PF09485
InterPro IPR013382
CDD cd09670

Evolution and diversity[edit]

The basic model of CRISPR evolution is newly incorporated spacers driving phages to mutate their genomes to avoid the bacterial immune response, creating diversity in both the phage and host populations. To fight off a phage infection, the sequence of the CRISPR spacer must correspond perfectly to the sequence of the target phage gene. Phages can continue to infect their hosts given point mutations in the spacer.[110] Similar stringency is required in PAM or the bacterial strain remains phage sensitive.[86][110]

A study of 124 S. thermophilus strains showed that 26% of all spacers were unique and that different CRISPR loci showed different rates of new spacer acquisition.[85] Some CRISPR loci evolve more rapidly than others, which allowed the strains' phylogenetic relationships to be determined. A comparative genomic analysis showed that E. coli and S. enterica evolve much more slowly than S. thermophilus. The latter's strains that diverged 250 thousand years ago still contained the same spacer complement.[111]

Metagenomic analysis of two acid mine drainage biofilms showed that one of the analyzed CRISPRs contained extensive deletions and spacer additions versus the other biofilm, suggesting a higher phage activity/prevalence in one community than the other.[58] In the oral cavity, a temporal study determined that 7-22% of spacers were shared over 17 months within an individual while less than 2% were shared across individuals.[94]

From the same environment a single strain was tracked using PCR primers specific to its CRISPR system. Broad-level results of spacer presence/absence showed significant diversity. However, this CRISPR added 3 spacers over 17 months,[94] suggesting that even in an environment with significant CRISPR diversity some loci evolve slowly.

CRISPRs were analysed from the metagenomes produced for the human microbiome project.[112] Although most were body-site specific, some within a body site are widely shared among individuals. One of these loci originated from streptococcal species and contained ~15,000 spacers, 50% of which were unique. Similar to the targeted studies of the oral cavity, some showed little evolution over time.[112]

CRISPR evolution has been studied in chemostats using S. thermophilus to directly examine spacer acquisition rates. In one week, S. thermophilus strains acquired up to three spacers when challenged with a single phage.[113] During the same interval the phage developed single nucleotide polymorphisms that became fixed in the population, suggesting that targeting had prevented phage replication absent these mutations.[113] Another S. thermophilus experiment showed that phages can still infect and replicate in hosts that have only one targeting spacer. Yet another showed that sensitive hosts can exist in environments with high phage titres.[114] The chemostat and observational studies suggest many nuances to CRISPR and phage (co)evolution.

Identification[edit]

CRISPRs are widely distributed among bacteria and archaea[65] and show some sequence similarities.[56] Their most notable characteristic is their repeating spacers and direct repeats. This characteristic makes CRISPRs easily identifiable in long sequences of DNA, since the number of repeats decreases the likelihood of a false positive match. Three programs used for CRISPR repeat identification search for regularly interspaced repeats in long sequences: CRT,[115] PILER-CR[116] and CRISPRfinder.[117]

Analysis of CRISPRs in metagenomic data is more challenging, as CRISPR loci do not typically assemble, due to their repetitive nature or through strain variation, which confuses assembly algorithms. Where many reference genomes are available, polymerase chain reaction (PCR) can be used to amplify CRISPR arrays and analyse spacer content.[85][94][118][119][120] However, this approach yields information only for specifically targeted CRISPRs and for organisms with sufficient representation in public databases to design reliable PCR primers.

The alternative is to extract and reconstruct CRISPR arrays from shotgun metagenomic data. This is computationally more difficult, particularly with second generation sequencing technologies (e.g. 454, Illumina), as the short read lengths prevent more than two or three repeat units appearing in a single read. CRISPR identification in raw reads has been achieved using purely denovo identification[121] or by using direct repeat sequences in partially assembled CRISPR arrays from contigs (overlapping DNA segments that together represent a consensus region of DNA)[112] and direct repeat sequences from published genomes[122] as a hook for identifying direct repeats in individual reads.

Evolutionary significance[edit]

A bioinformatic study showed that CRISPRs are evolutionarily conserved and cluster into related types. Many show signs of a conserved secondary structure.[56]

Through the CRISPR/Cas mechanism, bacteria can acquire immunity to certain phages and thus halt further transmission of targeted phages. For this reason, Eugene Koonin has described CRISPR/Cas as a Lamarckian inheritance mechanism.[123] However, this has been disputed by a recent critic noting "We should remember [Lamarck] for the good he contributed to science, not for things that resemble his theory only superficially. Indeed, thinking of CRISPR and other phenomena as Lamarckian only obscures the simple and elegant way evolution really works.[124]

Analysis of CRISPR sequences revealed coevolution of host and viral genomes.[125] Cas9 proteins are highly enriched in pathogenic and commensal bacteria. CRISPR/Cas-mediated gene regulation may contribute to the regulation of endogenous bacterial genes, particularly during interaction with eukaryotic hosts. For example, Francisella novicida uses a unique, small, CRISPR/Cas-associated RNA (scaRNA) to repress an endogenous transcript encoding a bacterial lipoprotein that is critical for F. novicida to dampen host response and promote virulence.[126]

Use by phages[edit]

Another way for bacteria to defend against phage infection is by having chromosomal islands. A subtype of chromosomal islands called phage-inducible chromosomal island (PICI) is excised from a bacterial chromosome upon phage infection and can inhibit phage replication.[127] The mechanisms that induce PICI excision and how PICI inhibits phage replication are not well understood. One study showed that lytic ICP1 phage, which specifically targets Vibrio cholerae serogroup O1, has acquired a CRISPR/Cas system that targets a V. cholera PICI-like element. The system has 2 CRISPR loci and 9 Cas genes. It seems to be homologous to the 1-F system found in Yersinia pestis. Moreover, like the bacterial CRISPR/Cas system, ICP1 CRISPR/Cas can acquire new sequences, which allows phage and host to co-evolve.[128]

Applications[edit]

By the end of 2014 some 600 research papers had been published that mentioned CRISPR.[129] The technology had been used to functionally inactivate genes in human cell lines and cells, to study Candida albicans, to modify yeasts used to make biofuels and to genetically modify crop strains.[129]

Genome engineering[edit]

CRISPR/Cas9 genome editing is carried out with a Type II CRISPR system. When utilized for genome editing, this system includes Cas9, CRISPR RNA (crRNA), trans-activating crRNA (tracrRNA) along with an optional section of DNA repair template that is utilized in either Non-Homologous End Joining (NHEJ) or Homology Directed Repair (HDR).

Overview of CRISPR Cas9 plasmid construction[130][131]

Major components[edit]

Component Function
crRNA Contains the guide RNA that locates the correct section of host DNA along with a region that binds to tracrRNA (generally in a hairpin loop form) forming an active complex.
tracrRNA Binds to crRNA and forms an active complex.
sgRNA Single guide RNAs are a combined RNA consisting of a tracrRNA and at least one crRNA
Cas9 Protein whose active form is able to modify DNA. Many variants exist with differing functions (i.e. single strand nicking, double strand break, DNA binding) due to Cas9's DNA site recognition function.
Repair template DNA that guides the cellular repair process allowing insertion of a specific DNA sequence

CRISPR/Cas9 often employs a plasmid to transfect the target cells. The main components of this plasmid are displayed in the image and listed in the table. The crRNA needs to be designed for each application as this is the sequence that Cas9 uses to identify and directly bind to the cell's DNA. The crRNA must bind only where editing is desired. The repair template is designed for each application, as it must overlap with the sequences on either side of the cut and code for the insertion sequence.

Multiple crRNA's and the tracrRNA can be packaged together to form a single-guide RNA (sgRNA). This sgRNA can be joined together with the Cas9 gene and made into a plasmid in order to be transfected into cells (see image for overview).

overview of the transfection and DNA cleaving by CRISPR Cas9 (crRNA and tracrRNA are often joined as one strand of RNA when designing a plasmid)[132]

Structure[edit]

CRISPR/Cas9 offers a high degree of fidelity and relatively simple construction. It depends on two factors for its specificity: the target sequence and the PAM. The target sequence is 20 bases long as part of each CRISPR locus in the crRNA array.[132] A typical crRNA array has multiple unique target sequences. Cas9 proteins select the correct location on the host's genome by utilizing the sequence to bond with base pairs on the host DNA. The sequence is not part of the Cas9 protein and as a result is customizable and can be independently synthesized.[133][134]

The PAM sequence on the host genome is recognized by the protein structure of Cas9 and generally cannot be easily modified to recognize a different sequence. However this is not too limiting as it is a short sequence and nonspecific (e.g. the SpCas9 PAM sequence is 5'-NGG-3' and in the human genome occurs roughly every 8 to 12 base pairs).[132]

Once these have been assembled into a plasmid and transfected into cells the Cas9 protein with help of the crRNA finds the correct sequence in the host cell's DNA and – depending on the Cas9 variant – creates a single or double strand break in the DNA.

Properly spaced single strand breaks in the host DNA can trigger homology directed repair, which is less error prone than non-homologous end joining that typically follows a double strand break. Providing a DNA repair template allows for the insertion of a specific DNA sequence at an exact location within the genome. The repair template should extend 40 to 90 base pairs beyond the Cas9 induced DNA break.[132] The goal is for the cell's HDR process to utilize the provided repair template and thereby incorporate the new sequence into the genome. Once incorporated, this new sequence is now part of the cell's genetic material and passes into its daughter cells.

Many online tools are available to aid in designing effective sgRNA sequences.[135]

Delivery[edit]

Scientists can use viral or non-viral system for delivery of the Cas9 and gRNA into target cells. Electroporation of DNA, RNA or ribonucleocomplexes is the most common and cheapest system. This technique was used to edit CXCR4 and PD-1, knocking in new sequences to replace specific genetic “letters” in these proteins. The group was then able to sort the cells, using cell surface markers, to help identify successfully edited cells.[136] Deep sequencing of a target site confirmed that knock-in genome modifications had occurred with up to ∼20% efficiency, which accounted for up to approximately one-third of total editing events.[137] However, hard-to-transfect cells (stem cells, neurons, hematopoietic cells, etc.) require more efficient delivery systems such as those based on lentivirus (LVs), adenovirus (AdV) and adeno-associated virus (AAV).

Editing[edit]

CRISPRs have been used to cut five[34] to 62 genes at once: pig cells have been engineered to inactivate all 62 Porcine Endogenous Retrovirus in the pig genome, which eliminated infection from the pig to human cells in culture.[138] CRISPR's low cost compared to alternatives is widely seen as revolutionary.[8][9]

Selective engineered redirection of the CRISPR/Cas system was first demonstrated in 2012 in:[139][140]

  • Immunization of industrially important bacteria, including some used in food production and large-scale fermentation
  • Cellular or organism RNA-guided genome engineering. Proof of concept studies demonstrated examples both in vitro[10][38][67] and in vivo[50][141][142]
  • Bacterial strain discrimination by comparison of spacer sequences

Knockdown/activation[edit]

Main article: CRISPR interference

Using “dead” versions of Cas9 (dCas9) eliminates CRISPR’s DNA-cutting ability, while preserving its ability to target desirable sequences. Multiple groups added various regulatory factors to dCas9s, enabling them to turn almost any gene on or off or subtly adjust its level of activity.[143] Like RNAi, CRISPR interference (CRISPRi) turns off genes in a reversible fashion by targeting, but not cutting a site. The targeted site is methylated, epigenetically modifying the gene. This modification inhibits transcription. Cas9 is an effective way of targeting and silencing specific genes at the DNA level.[144] In bacteria, the presence of Cas9 alone is enough to block transcription. For mammalian applications, a section of protein is added. Its guide RNA targets regulatory DNA sequences called promoters that immediately precede the target gene.[34]

Cas9 was used to carry synthetic transcription factors that activated specific human genes. The technique achieved a strong effect by targeting multiple CRISPR constructs to slightly different locations on the gene's promoter.[34]

RNA editing[edit]

In 2016 researchers demonstrated that CRISPR from an ordinary mouth bacterium could be used to edit RNA. The researchers searched databases containing hundreds of millions of genetic sequences for those that resembled Crispr genes. With Zhang they considered the fusobacteria Leptotrichia shahii. It had a group of genes that resembled CRISPR genes, but with important differences. When the researchers equipped other bacteria with these genes, which they called C2c2, they found that the organisms gained a novel defense.[145]

Many viruses encode their genetic information in RNA rather than DNA that they repurpose to make new viruses. HIV and poliovirus are such viruses. Bacteria with C2c2 make molecules that can dismember RNA, destroying the virus. Tailoring these genes opened any RNA molecule to editing.[145]

Disease models[edit]

CRISPR simplifies creation of animals for research that mimic disease or show what happens when a gene is knocked down or mutated. CRISPR may be used at the germline level to create animals where the gene is changed everywhere, or it may be targeted at non-germline cells.[146][147][148]

CRISPR can be utilized to create human cellular models of disease. For instance, CRISPR was applied to human pluripotent stem cells to introduce targeted mutations in genes relevant to polycystic kidney disease (PKD) and focal segmental glomerulosclerosis (FSG).[149] These CRISPR-modified pluripotent stem cells were subsequently grown into human kidney organoids that exhibited disease-specific phenotypes. Kidney organoids from stem cells with PKD populations formed large, translucent cyst structures from kidney tubules. Kidney organoids with mutations in a gene linked to FSG developed junctional defects between podocytes, the filtering cells affected in that disease. Importantly, these disease phenotypes were absent in control organoids of identical genetic background, but lacking the CRISPR modifications.[149]

A similar approach has been taken to model long QT syndrome in cardiomyocytes derived from pluripotent stem cells.[150] These CRISPR-generated cellular models, with isogenic controls, provide a new way to study human diseases and test drugs.

Gene drive[edit]

Main article: Gene drive

In 2003 evolutionary biologist Austin Burt envisioned attaching a gene that coded for a desired trait to “selfish” DNA elements that could copy themselves from one chromosome position to another. That would bias daughter cells to inherit it, quickly spreading it throughout a population. In 2015 a U.S. team used CRISPR to create a “mutagenic chain reaction” that drove a pigmentation trait in lab-grown Drosophila to the next generation with 97% efficiency. With another research group they created a gene drive in mosquitoes that spread genes that prevented the insects from harboring malaria parasites. Only weeks later, the team reported a second drive with genes that rendered female mosquitoes infertile and could quickly wipe out a population. The work was done in the lab, stimulating debates over the desirability of field testing.[143]

Biomedicine[edit]

CRISPR/Cas-based "RNA-guided nucleases" can be used to target virulence factors, genes encoding antibiotic resistance, and other medically relevant sequences of interest. This technology thus represents a novel form of antimicrobial therapy and a strategy by which to manipulate bacterial populations.[151] Some of the affected genes are tied to human diseases, including those involved in muscle differentiation, cancer, inflammation and fetal hemoglobin.[34]

Research suggests that CRISPR is an effective way to limit replication of multiple herpesviruses. It was even able to eradicate viral DNA in the case of Epstein-Barr virus (EBV). Anti-herpesvirus CRISPRs have several promising applications, such as removing cancer-causing EBV from tumor cells, helping rid donated organs for immunocompromised patients of viral invaders, or preventing cold sore outbreaks and recurrent eye infections by blocking HSV-1 reactivation. As of August 2016, these await testing in animal models or humans.[152]

Clinical researchers are applying it to develop tissue-based treatments for cancer and other diseases.[143]

CRISPR may revive the concept of transplanting animal organs into people. Retroviruses present in animal genomes could harm transplant recipients. In 2015 a team eliminated 62 copies of a retrovirus’s DNA from the pig genome.[143]

It may also have applications in tissue engineering and regenerative medicine, such as by creating human blood vessels that lack expression of MHC class II proteins, which often cause transplant rejection.[153]

Gene function[edit]

In 2015, multiple studies attempted to systematically disable each individual human gene, in an attempt to identify which genes were essential to human biology. Between 1,600 and 1,800 genes passed this test—of the 20,000 or so known human genes. Such genes are more strongly activated, and unlikely to carry disabling mutations. They are more likely to have indispensable counterparts in other species. They build proteins that unite to form larger collaborative complexes. The studies also catalogued the essential genes in four cancer-cell lines and identified genes that are expendable in healthy cells, but crucial in specific tumor types and drugs that could target these rogue genes.[154]

The specific functions of some 18 percent of the essential genes are unidentified. In one 2015 targeting experiment, disabling individual genes in groups of cells attempted to identify those involved in resistance to a melanoma drug. Each such gene manipulation is itself a separate "drug", potentially opening the entire genome to CRISPR-based regulation.[143]

In vitro genetic depletion[edit]

Unenriched sequencing libraries often have abundant undesired sequences. Cas9 can specifically deplete the undesired sequences with double strand breakage with up to 99% efficiency and without significant off-target effects as seen with restriction enzymes. Treatment with Cas9 can deplete abundant rRNA while increasing pathogen sensitivity in RNA-seq libraries.[155]

Patents and commercialization[edit]

As of December 2014, patent rights to CRISPR were contested. Several companies had formed to develop related drugs and research tools.[156] As companies ramp up financing, doubts as to whether or not CRISPR can be quickly monetized were raised.[157]

As of November 2013, SAGE Labs (now part of Horizon Discovery group) had exclusive rights from one of those companies to produce and sell genetically engineered rats and non-exclusive rights for mouse and rabbit models.[158] By 2015, Thermo Fisher Scientific had licensed intellectual property from ToolGen to develop CRISPR reagent kits.[159]

Society and culture[edit]

Human germline modification[edit]

At least four labs in the US, labs in China and the UK, and a US biotechnology company called Ovascience announced plans or ongoing research to apply CRISPR to human embryos.[160] Scientists, including a CRISPR co-inventor, urged a worldwide moratorium on applying CRISPR to the human germline, especially for clinical use. They said "scientists should avoid even attempting, in lax jurisdictions, germline genome modification for clinical application in humans" until the full implications "are discussed among scientific and governmental organizations".[52][161] These scientists support basic research on CRISPR and do not see CRISPR as developed enough for any clinical use in making heritable changes to people.[162]

In April 2015, Chinese scientists reported results of an attempt to alter the DNA of non-viable human embryos using CRISPR to correct a mutation that causes beta thalassemia, a lethal heritable disorder.[163][164] The study had previously been rejected by both Nature and Science in part because of ethical concerns; the journals had no comment.[165] The experiments resulted in changing only some genes, and had off-target effects on other genes. The researchers stated that CRISPR is not ready for clinical application in reproductive medicine.[165] In April 2016 Chinese scientists were reported to have made a second unsuccessful attempt to alter the DNA of non-viable human embryos using CRISPR - this time to alter the CCR5 gene to make the embryo HIV resistant.[166]

In December 2015, the International Summit on Human Gene Editing took place in Washington under the guidance of David Baltimore. Members of national scientific academies of America, Britain and China discussed the ethics of germline modification. They agreed to support basic and clinical research under appropriate legal and ethical guidelines. A specific distinction was made between clinical use in somatic cells, where the effects of edits are limited to a single individual, versus germline cells, where genome changes could be inherited by future generations. Heritable modifications could have unintended and far-reaching consequences for human evolution, genetically (e.g. gene/environment interactions) and culturally (e.g. Social Darwinism). Altering of gametocytes and embryos to generate inheritable changes in humans was thus claimed irresponsible. In addition, they agreed to initiate an international forum to address such concerns and harmonize regulations countries.[167]

In February 2016, British scientists were given permission by regulators to genetically modify human embryos by using CRISPR-Cas9 and related techniques. The embryos were to be destroyed after seven days.[168][169]

Recognition[edit]

In 2012 and 2013, CRISPR was a runner-up in Science Magazine's Breakthrough of the Year award. In 2015, it was the winner of that award.[143] CRISPR was named as one of MIT Technology Review's 10 breakthroughs technologies in 2014 and 2016.[170][171]

Alternative cutters[edit]

See also[edit]

Notes[edit]

  1. ^ 71/79 Archaea, 463/1008 Bacteria CRISPRdb, Date: 19.6.2010 Archived May 16, 2015, at the Wayback Machine.

[62]

References[edit]

  1. ^ a b c Horvath P, Barrangou R (January 2010). "CRISPR/Cas, the immune system of bacteria and archaea". Science. 327 (5962): 167–70. Bibcode:2010Sci...327..167H. doi:10.1126/Science.1179555. PMID 20056882. 
  2. ^ Sawyer E (9 February 2013). "Editing Genomes with the Bacterial Immune System". Scitable. Nature Publishing Group. Retrieved 6 April 2015. 
  3. ^ a b c d Marraffini LA, Sontheimer EJ (March 2010). "CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea". Nature Reviews Genetics. 11 (3): 181–90. doi:10.1038/nrg2749. PMC 2928866free to read. PMID 20125085.  open access publication - free to read
  4. ^ Redman M, King A, Watson C, King D (April 2016). "What is CRISPR/Cas9?". Archives of Disease in Childhood. Education and Practice Edition. 101: 213–215. doi:10.1136/archdischild-2016-310459. PMID 27059283. 
  5. ^ Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P (March 2007). "CRISPR provides acquired resistance against viruses in prokaryotes". Science. 315 (5819): 1709–12. Bibcode:2007Sci...315.1709B. doi:10.1126/science.1138140. PMID 17379808.  (registration required)
  6. ^ a b Marraffini LA, Sontheimer EJ (December 2008). "CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA". Science. 322 (5909): 1843–5. Bibcode:2008Sci...322.1843M. doi:10.1126/science.1165771. PMC 2695655free to read. PMID 19095942. open access publication - free to read
  7. ^ a b Grissa I, Vergnaud G, Pourcel C (2007). "The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats". BMC Bioinformatics. 8: 172. doi:10.1186/1471-2105-8-172. PMC 1892036free to read. PMID 17521438. open access publication - free to read
  8. ^ a b Ledford, Heidi (3 June 2015). "CRISPR, the disruptor". News Feature. Nature. 522 (7554). 
  9. ^ a b Snyder B (21 August 2014). "New technique accelerates genome editing process". research news @ Vanderbilt. Nashville, Tennessee: Vanderbilt University. 
  10. ^ a b Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, Bruhn L, Porteus MH (September 2015). "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells". Nature Biotechnology. 33 (9): 985–9. doi:10.1038/nbt.3290. PMID 26121415.  Closed access
  11. ^ Mali P, Esvelt KM, Church GM (October 2013). "Cas9 as a versatile tool for engineering biology". Nature Methods. 10 (10): 957–63. doi:10.1038/nmeth.2649. PMC 4051438free to read. PMID 24076990. open access publication - free to read
  12. ^ a b Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F (October 2015). "Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system". Cell. 163 (3): 759–71. doi:10.1016/j.cell.2015.09.038. PMID 26422227. 
  13. ^ a b Fonfara I, Richter H, Bratovič M, Le Rhun A, Charpentier E (April 2016). "The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA". Nature. 532 (7600): 517–21. doi:10.1038/nature17945. PMID 27096362. 
  14. ^ "Even CRISPR". The Economist. ISSN 0013-0613. Retrieved 2016-05-25. 
  15. ^ Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, Shmakov S, Makarova KS, Semenova E, Minakhin L, Severinov K, Regev A, Lander ES, Koonin EV, Zhang F (June 2016). "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector". Science. doi:10.1126/science.aaf5573. PMID 27256883. 
  16. ^ Ledford H (March 2016). "CRISPR: gene editing is just the beginning". Nature. 531 (7593): 156–9. doi:10.1038/531156a. PMID 26961639. 
  17. ^ Maxmen A (August 2015). "The Genesis Engine". WIRED. Retrieved 2016-06-05. 
  18. ^ 2015 Breakthrough of the Year, Science Magazine, American Association for the Advancement of Science, 2016,
  19. ^ Ledford H (June 2015). "CRISPR, the disruptor". Nature. 522 (7554): 20–4. doi:10.1038/522020a. PMID 26040877. 
  20. ^ Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A (December 1987). "Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product". Journal of Bacteriology. 169 (12): 5429–33. PMC 213968free to read. PMID 3316184. open access publication - free to read
  21. ^ a b c d e f g Hsu PD, Lander ES, Zhang F (June 2014). "Development and applications of CRISPR-Cas9 for genome engineering". Cell. 157 (6): 1262–78. doi:10.1016/j.cell.2014.05.010. PMC 4343198free to read. PMID 24906146. 
  22. ^ van Soolingen D, de Hass PE, Hermans PW, Groenen PM, van Embden JD (August 1993). "Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis". J Clin Microbiol. 31 (8): 1987–95. PMC 265684free to read. PMID 7690367. 
  23. ^ Groenen PM, Bunschoten AE, van Soolingen D, van Embden JD (1993). "Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method". Molecular Microbiology. 10: 1057–65. doi:10.1111/j.1365-2958.1993.tb00976.x. PMID 7934856. 
  24. ^ Mojica FJ, Ferrer C, Juez G, Rodríguez-Valera F (1995). "Long stretches of short tandem repeats are present in the largest replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and could be involved in replicon partitioning". Molecular Microbiology. 17: 85–93. doi:10.1111/j.1365-2958.1995.mmi_17010085.x. PMID 7476211. 
  25. ^ Mojica FJ, Díez-Villaseñor C, Soria E, Juez G (April 2000). "Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria". Molecular Microbiology. 36 (1): 244–6. doi:10.1046/j.1365-2958.2000.01838.x. PMID 10760181. open access publication - free to read
  26. ^ Jansen R, Embden JD, Gaastra W, Schouls LM (March 2002). "Identification of genes that are associated with DNA repeats in prokaryotes". Molecular Microbiology. 43 (6): 1565–75. doi:10.1046/j.1365-2958.2002.02839.x. PMID 11952905. 
  27. ^ a b c d Pourcel C, Salvignol G, Vergnaud G (March 2005). "CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies". Microbiology. 151 (Pt 3): 653–63. doi:10.1099/mic.0.27437-0. PMID 15758212. open access publication - free to read
  28. ^ a b Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E (February 2005). "Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements". Journal of Molecular Evolution. 60 (2): 174–82. doi:10.1007/s00239-004-0046-3. PMID 15791728. Closed access
  29. ^ a b c d Bolotin A, Quinquis B, Sorokin A, Ehrlich SD (August 2005). "Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin". Microbiology. 151 (Pt 8): 2551–61. doi:10.1099/mic.0.28048-0. PMID 16079334. open access publication - free to read
  30. ^ Morange M (June 2015). "What history tells us XXXVII. CRISPR-Cas: The discovery of an immune system in prokaryotes". Journal of Biosciences. 40 (2): 221–3. doi:10.1007/s12038-015-9532-6. PMID 25963251. open access publication - free to read
  31. ^ Lander ES (January 2016). "The Heroes of CRISPR". Cell. 164 (1-2): 18–28. doi:10.1016/j.cell.2015.12.041. PMID 26771483. 
  32. ^ Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV (2006). "A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action". Biology Direct. 1: 7. doi:10.1186/1745-6150-1-7. PMC 1462988free to read. PMID 16545108. 
  33. ^ a b c Marraffini LA (October 2015). "CRISPR-Cas immunity in prokaryotes". Nature. 526 (7571): 55–61. doi:10.1038/nature15386. PMID 26432244. 
  34. ^ a b c d e f Pennisi E (August 2013). "The CRISPR craze". News Focus. Science. 341 (6148): 833–6. doi:10.1126/science.341.6148.833. PMID 23970676. Closed access
  35. ^ a b Garneau JE, Dupuis M, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadán AH, Moineau S (November 2010). "The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA". Nature. 468 (7320): 67–71. doi:10.1038/nature09523. PMID 21048762. 
  36. ^ a b c d Wiedenheft B, Sternberg SH, Doudna JA (February 2012). "RNA-guided genetic silencing systems in bacteria and archaea". Nature. 482 (7385): 331–8. Bibcode:2012Natur.482..331W. doi:10.1038/nature10886. PMID 22337052. Closed access
  37. ^ Barrangou R (2015). "Diversity of CRISPR-Cas immune systems and molecular machines". Genome Biology. 16: 247. doi:10.1186/s13059-015-0816-9. PMC 4638107free to read. PMID 26549499. 
  38. ^ a b Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (August 2012). "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity". Science. 337 (6096): 816–21. Bibcode:2012Sci...337..816J. doi:10.1126/science.1225829. PMID 22745249. open access publication - free to read
  39. ^ Barrangou R, van Pijkeren JP (February 2016). "Exploiting CRISPR-Cas immune systems for genome editing in bacteria". Current Opinion in Biotechnology. 37: 61–8. doi:10.1016/j.copbio.2015.10.003. PMID 26629846. 
  40. ^ Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (February 2013). "Multiplex genome engineering using CRISPR/Cas systems". Science. 339 (6121): 819–23. doi:10.1126/science.1231143. PMC 3795411free to read. PMID 23287718. 
  41. ^ Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (February 2013). "RNA-guided human genome engineering via Cas9". Science. 339 (6121): 823–6. doi:10.1126/science.1232033. PMC 3712628free to read. PMID 23287722. 
  42. ^ DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM (April 2013). "Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems". Nucleic Acids Research. 41 (7): 4336–43. doi:10.1093/nar/gkt135. PMC 3627607free to read. PMID 23460208. open access publication - free to read
  43. ^ Zhang GC, Kong II, Kim H, Liu JJ, Cate JH, Jin YS (December 2014). "Construction of a quadruple auxotrophic mutant of an industrial polyploid saccharomyces cerevisiae strain by using RNA-guided Cas9 nuclease". Applied and Environmental Microbiology. 80 (24): 7694–701. doi:10.1128/AEM.02310-14. PMID 25281382. 
  44. ^ Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, Kwak S, Sung BH, Sohn JH, Walukiewicz HE, Rao CV, Jin YS (April 2016). "Metabolic Engineering of Probiotic Saccharomyces boulardii". Applied and Environmental Microbiology. 82 (8): 2280–7. doi:10.1128/AEM.00057-16. PMID 26850302. 
  45. ^ Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK (March 2013). "Efficient genome editing in zebrafish using a CRISPR-Cas system". Nature Biotechnology. 31 (3): 227–9. doi:10.1038/nbt.2501. PMC 3686313free to read. PMID 23360964. open access publication - free to read
  46. ^ Gratz SJ, Cummings AM, Nguyen JN, Hamm DC, Donohue LK, Harrison MM, Wildonger J, O'Connor-Giles KM (August 2013). "Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease". Genetics. 194 (4): 1029–35. doi:10.1534/genetics.113.152710. PMC 3730909free to read. PMID 23709638. open access publication - free to read
  47. ^ Flowers GP, Timberlake AT, McLean KC, Monaghan JR, Crews CM (May 2014). "Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided nuclease". Development. 141 (10): 2165–71. doi:10.1242/dev.105072. PMC 4011087free to read. PMID 24764077. open access publication - free to read
  48. ^ Friedland AE, Tzur YB, Esvelt KM, Colaiácovo MP, Church GM, Calarco JA (August 2013). "Heritable genome editing in C. elegans via a CRISPR-Cas9 system". Nature Methods. 10 (8): 741–3. doi:10.1038/nmeth.2532. PMC 3822328free to read. PMID 23817069. open access publication - free to read
  49. ^ Jiang W, Zhou H, Bi H, Fromm M, Yang B, Weeks DP (November 2013). "Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification in Arabidopsis, tobacco, sorghum and rice". Nucleic Acids Research. 41 (20): e188. doi:10.1093/nar/gkt780. PMC 3814374free to read. PMID 23999092. open access publication - free to read
  50. ^ a b Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R (May 2013). "One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering". Cell. 153 (4): 910–8. doi:10.1016/j.cell.2013.04.025. PMC 3969854free to read. PMID 23643243. open access publication - free to read
  51. ^ Guo X, Li XJ (July 2015). "Targeted genome editing in primate embryos". Cell Research. 25 (7): 767–8. doi:10.1038/cr.2015.64. PMID 26032266. Closed access
  52. ^ a b Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, Greely HT, Jinek M, Martin GS, Penhoet E, Puck J, Sternberg SH, Weissman JS, Yamamoto KR (April 2015). "Biotechnology. A prudent path forward for genomic engineering and germline gene modification". Science. 348 (6230): 36–8. Bibcode:2015Sci...348...36B. doi:10.1126/science.aab1028. PMC 4394183free to read. PMID 25791083. Closed access
  53. ^ Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS (November 2013). "CRISPR interference (CRISPRi) for sequence-specific control of gene expression". Nature Protocols. 8 (11): 2180–96. doi:10.1038/nprot.2013.132. PMID 24136345. open access publication - free to read
  54. ^ Young S (11 February 2014). "CRISPR and Other Genome Editing Tools Boost Medical Research and Gene Therapy's Reach". MIT Technology Review. Cambridge, Massachusetts: Massachusetts Institute of Technology. Retrieved 2014-04-13. 
  55. ^ a b c Haft DH, Selengut J, Mongodin EF, Nelson KE (November 2005). "A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes". PLoS Computational Biology. 1 (6): e60. Bibcode:2005PLSCB...1...60H. doi:10.1371/journal.pcbi.0010060. PMC 1282333free to read. PMID 16292354. open access publication - free to read
  56. ^ a b c d Kunin V, Sorek R, Hugenholtz P (2007). "Evolutionary conservation of sequence and secondary structures in CRISPR repeats". Genome Biology. 8 (4): R61. doi:10.1186/gb-2007-8-4-r61. PMC 1896005free to read. PMID 17442114. open access publication - free to read
  57. ^ Stern A, Keren L, Wurtzel O, Amitai G, Sorek R (August 2010). "Self-targeting by CRISPR: gene regulation or autoimmunity?". Trends in Genetics. 26 (8): 335–40. doi:10.1016/j.tig.2010.05.008. PMC 2910793free to read. PMID 20598393. open access publication - free to read
  58. ^ a b c Tyson GW, Banfield JF (January 2008). "Rapidly evolving CRISPRs implicated in acquired resistance of microorganisms to viruses". Environmental Microbiology. 10 (1): 200–7. doi:10.1111/j.1462-2920.2007.01444.x. PMID 17894817. Closed access
  59. ^ Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, Barrangou R, Brouns SJ, Charpentier E, Haft DH, Horvath P, Moineau S, Mojica FJ, Terns RM, Terns MP, White MF, Yakunin AF, Garrett RA, van der Oost J, Backofen R, Koonin EV (November 2015). "An updated evolutionary classification of CRISPR-Cas systems". Nature Reviews. Microbiology. 13 (11): 722–36. doi:10.1038/nrmicro3569. PMID 26411297. 
  60. ^ a b Deng L, Garrett RA, Shah SA, Peng X, She Q (March 2013). "A novel interference mechanism by a type IIIB CRISPR-Cmr module in Sulfolobus". Molecular Microbiology. 87 (5): 1088–99. doi:10.1111/mmi.12152. PMID 23320564. open access publication - free to read
  61. ^ Sinkunas T, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V (April 2011). "Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system". The EMBO Journal. 30 (7): 1335–42. doi:10.1038/emboj.2011.41. PMC 3094125free to read. PMID 21343909. 
  62. ^ a b Huo Y, Nam KH, Ding F, Lee H, Wu L, Xiao Y, Farchione MD, Zhou S, Rajashankar K, Kurinov I, Zhang R, Ke A (September 2014). "Structures of CRISPR Cas3 offer mechanistic insights into Cascade-activated DNA unwinding and degradation". Nature Structural & Molecular Biology. 21 (9): 771–7. doi:10.1038/nsmb.2875. PMC 4156918free to read. PMID 25132177. 
  63. ^ a b c Aliyari R, Ding SW (January 2009). "RNA-based viral immunity initiated by the Dicer family of host immune receptors". Immunological Reviews. 227 (1): 176–88. doi:10.1111/j.1600-065X.2008.00722.x. PMC 2676720free to read. PMID 19120484. open access publication - free to read
  64. ^ Cass SD, Haas KA, Stoll B, Alkhnbashi O, Sharma K, Urlaub H, Backofen R, Marchfelder A, Bolt EL (May 2015). "The role of Cas8 in type I CRISPR interference". Bioscience Reports. 35 (3). doi:10.1042/BSR20150043. PMID 25940458. open access publication - free to read
  65. ^ a b Chylinski K, Makarova KS, Charpentier E, Koonin EV (June 2014). "Classification and evolution of type II CRISPR-Cas systems". Nucleic Acids Research. 42 (10): 6091–105. doi:10.1093/nar/gku241. PMC 4041416free to read. PMID 24728998. open access publication - free to read
  66. ^ a b Makarova KS, Aravind L, Wolf YI, Koonin EV (2011). "Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems". Biology Direct. 6: 38. doi:10.1186/1745-6150-6-38. PMC 3150331free to read. PMID 21756346. open access publication - free to read
  67. ^ a b c d Gasiunas G, Barrangou R, Horvath P, Siksnys V (September 2012). "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria". Proceedings of the National Academy of Sciences of the United States of America. 109 (39): E2579–86. Bibcode:2012PNAS..109E2579G. doi:10.1073/pnas.1208507109. PMC 3465414free to read. PMID 22949671. open access publication - free to read
  68. ^ Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D, Marraffini LA (March 2015). "Cas9 specifies functional viral targets during CRISPR-Cas adaptation". Nature. 519 (7542): 199–202. Bibcode:2015Natur.519..199H. doi:10.1038/nature14245. PMC 4385744free to read. PMID 25707807. Closed access
  69. ^ Nam KH, Kurinov I, Ke A (September 2011). "Crystal structure of clustered regularly interspaced short palindromic repeats (CRISPR)-associated Csn2 protein revealed Ca2+-dependent double-stranded DNA binding activity". The Journal of Biological Chemistry. 286 (35): 30759–68. doi:10.1074/jbc.M111.256263. PMC 3162437free to read. PMID 21697083. 
  70. ^ Chylinski K, Le Rhun A, Charpentier E (May 2013). "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems". RNA Biology. 10 (5): 726–37. doi:10.4161/rna.24321. PMC 3737331free to read. PMID 23563642. open access publication - free to read
  71. ^ a b Dugar G, Herbig A, Förstner KU, Heidrich N, Reinhardt R, Nieselt K, Sharma CM (May 2013). "High-resolution transcriptome maps reveal strain-specific regulatory features of multiple Campylobacter jejuni isolates". PLoS Genetics. 9 (5): e1003495. doi:10.1371/journal.pgen.1003495. PMC 3656092free to read. PMID 23696746. 
  72. ^ Hatoum-Aslan A, Maniv I, Marraffini LA (December 2011). "Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site". Proceedings of the National Academy of Sciences of the United States of America. 108 (52): 21218–22. Bibcode:2011PNAS..10821218H. doi:10.1073/pnas.1112832108. PMC 3248500free to read. PMID 22160698. 
  73. ^ a b Yosef I, Goren MG, Qimron U (July 2012). "Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli". Nucleic Acids Research. 40 (12): 5569–76. doi:10.1093/nar/gks216. PMC 3384332free to read. PMID 22402487. 
  74. ^ a b c d Swarts DC, Mosterd C, van Passel MW, Brouns SJ (2012). "CRISPR interference directs strand specific spacer acquisition". PloS One. 7 (4): e35888. Bibcode:2012PLoSO...735888S. doi:10.1371/journal.pone.0035888. PMC 3338789free to read. PMID 22558257. 
  75. ^ Babu M, Beloglazova N, Flick R, Graham C, Skarina T, Nocek B, Gagarinova A, Pogoutse O, Brown G, Binkowski A, Phanse S, Joachimiak A, Koonin EV, Savchenko A, Emili A, Greenblatt J, Edwards AM, Yakunin AF (January 2011). "A dual function of the CRISPR-Cas system in bacterial antivirus immunity and DNA repair". Molecular Microbiology. 79 (2): 484–502. doi:10.1111/j.1365-2958.2010.07465.x. PMC 3071548free to read. PMID 21219465. 
  76. ^ Han D, Lehmann K, Krauss G (June 2009). "SSO1450--a CAS1 protein from Sulfolobus solfataricus P2 with high affinity for RNA and DNA". FEBS Letters. 583 (12): 1928–32. doi:10.1016/j.febslet.2009.04.047. PMID 19427858. 
  77. ^ Wiedenheft B, Zhou K, Jinek M, Coyle SM, Ma W, Doudna JA (June 2009). "Structural basis for DNase activity of a conserved protein implicated in CRISPR-mediated genome defense". Structure. 17 (6): 904–12. doi:10.1016/j.str.2009.03.019. PMID 19523907. 
  78. ^ Beloglazova N, Brown G, Zimmerman MD, Proudfoot M, Makarova KS, Kudritska M, Kochinyan S, Wang S, Chruszcz M, Minor W, Koonin EV, Edwards AM, Savchenko A, Yakunin AF (July 2008). "A novel family of sequence-specific endoribonucleases associated with the clustered regularly interspaced short palindromic repeats". The Journal of Biological Chemistry. 283 (29): 20361–71. doi:10.1074/jbc.M803225200. PMC 2459268free to read. PMID 18482976. 
  79. ^ Samai P, Smith P, Shuman S (December 2010). "Structure of a CRISPR-associated protein Cas2 from Desulfovibrio vulgaris". Acta Crystallographica Section F. 66 (Pt 12): 1552–6. doi:10.1107/S1744309110039801. PMC 2998353free to read. PMID 21139194. 
  80. ^ Nam KH, Ding F, Haitjema C, Huang Q, DeLisa MP, Ke A (October 2012). "Double-stranded endonuclease activity in Bacillus halodurans clustered regularly interspaced short palindromic repeats (CRISPR)-associated Cas2 protein". The Journal of Biological Chemistry. 287 (43): 35943–52. doi:10.1074/jbc.M112.382598. PMC 3476262free to read. PMID 22942283. 
  81. ^ a b Nuñez JK, Kranzusch PJ, Noeske J, Wright AV, Davies CW, Doudna JA (June 2014). "Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity". Nature Structural & Molecular Biology. 21 (6): 528–34. doi:10.1038/nsmb.2820. PMC 4075942free to read. PMID 24793649. 
  82. ^ Nuñez JK, Lee AS, Engelman A, Doudna JA (March 2015). "Integrase-mediated spacer acquisition during CRISPR-Cas adaptive immunity". Nature. 519 (7542): 193–8. doi:10.1038/nature14237. PMC 4359072free to read. PMID 25707795. 
  83. ^ Wang J, Li J, Zhao H, Sheng G, Wang M, Yin M, Wang Y (November 2015). "Structural and Mechanistic Basis of PAM-Dependent Spacer Acquisition in CRISPR-Cas Systems". Cell. 163 (4): 840–53. doi:10.1016/j.cell.2015.10.008. PMID 26478180. 
  84. ^ Nuñez JK, Harrington LB, Kranzusch PJ, Engelman AN, Doudna JA (November 2015). "Foreign DNA capture during CRISPR-Cas adaptive immunity". Nature. 527 (7579): 535–8. doi:10.1038/nature15760. PMID 26503043. 
  85. ^ a b c d Horvath P, Romero DA, Coûté-Monvoisin AC, Richards M, Deveau H, Moineau S, Boyaval P, Fremaux C, Barrangou R (February 2008). "Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus". Journal of Bacteriology. 190 (4): 1401–12. doi:10.1128/JB.01415-07. PMC 2238196free to read. PMID 18065539. 
  86. ^ a b c Deveau H, Barrangou R, Garneau JE, Labonté J, Fremaux C, Boyaval P, Romero DA, Horvath P, Moineau S (February 2008). "Phage response to CRISPR-encoded resistance in Streptococcus thermophilus". Journal of Bacteriology. 190 (4): 1390–400. doi:10.1128/JB.01412-07. PMC 2238228free to read. PMID 18065545. 
  87. ^ Mojica FJ, Díez-Villaseñor C, García-Martínez J, Almendros C (March 2009). "Short motif sequences determine the targets of the prokaryotic CRISPR defence system". Microbiology. 155 (Pt 3): 733–40. doi:10.1099/mic.0.023960-0. PMID 19246744. 
  88. ^ a b Lillestøl RK, Shah SA, Brügger K, Redder P, Phan H, Christiansen J, Garrett RA (April 2009). "CRISPR families of the crenarchaeal genus Sulfolobus: bidirectional transcription and dynamic properties". Molecular Microbiology. 72 (1): 259–72. doi:10.1111/j.1365-2958.2009.06641.x. PMID 19239620. 
  89. ^ a b Shah SA, Hansen NR, Garrett RA (February 2009). "Distribution of CRISPR spacer matches in viruses and plasmids of crenarchaeal acidothermophiles and implications for their inhibitory mechanism". Biochemical Society Transactions. 37 (Pt 1): 23–8. doi:10.1042/BST0370023. PMID 19143596. 
  90. ^ a b Díez-Villaseñor C, Guzmán NM, Almendros C, García-Martínez J, Mojica FJ (May 2013). "CRISPR-spacer integration reporter plasmids reveal distinct genuine acquisition specificities among CRISPR-Cas I-E variants of Escherichia coli". RNA Biology. 10 (5): 792–802. doi:10.4161/rna.24023. PMC 3737337free to read. PMID 23445770. 
  91. ^ a b c Erdmann S, Garrett RA (September 2012). "Selective and hyperactive uptake of foreign DNA by adaptive immune systems of an archaeon via two distinct mechanisms". Molecular Microbiology. 85 (6): 1044–56. doi:10.1111/j.1365-2958.2012.08171.x. PMC 3468723free to read. PMID 22834906. 
  92. ^ a b Shah SA, Erdmann S, Mojica FJ, Garrett RA (May 2013). "Protospacer recognition motifs: mixed identities and functional diversity". RNA Biology. 10 (5): 891–9. doi:10.4161/rna.23764. PMC 3737346free to read. PMID 23403393. 
  93. ^ Andersson AF, Banfield JF (May 2008). "Virus population dynamics and acquired virus resistance in natural microbial communities". Science. 320 (5879): 1047–50. Bibcode:2008Sci...320.1047A. doi:10.1126/science.1157358. PMID 18497291. 
  94. ^ a b c d Pride DT, Sun CL, Salzman J, Rao N, Loomer P, Armitage GC, Banfield JF, Relman DA (January 2011). "Analysis of streptococcal CRISPRs from human saliva reveals substantial sequence diversity within and between subjects over time". Genome Research. 21 (1): 126–36. doi:10.1101/gr.111732.110. PMC 3012920free to read. PMID 21149389. 
  95. ^ a b Goren MG, Yosef I, Auster O, Qimron U (October 2012). "Experimental definition of a clustered regularly interspaced short palindromic duplicon in Escherichia coli". Journal of Molecular Biology. 423 (1): 14–6. doi:10.1016/j.jmb.2012.06.037. PMID 22771574. 
  96. ^ a b c Datsenko KA, Pougach K, Tikhonov A, Wanner BL, Severinov K, Semenova E (2012). "Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system". Nature Communications. 3: 945. Bibcode:2012NatCo...3E.945D. doi:10.1038/ncomms1937. PMID 22781758. 
  97. ^ Gesner EM, Schellenberg MJ, Garside EL, George MM, Macmillan AM (June 2011). "Recognition and maturation of effector RNAs in a CRISPR interference pathway". Nature Structural & Molecular Biology. 18 (6): 688–92. doi:10.1038/nsmb.2042. PMID 21572444. 
  98. ^ Sashital DG, Jinek M, Doudna JA (June 2011). "An RNA-induced conformational change required for CRISPR RNA cleavage by the endoribonuclease Cse3". Nature Structural & Molecular Biology. 18 (6): 680–7. doi:10.1038/nsmb.2043. PMID 21572442. 
  99. ^ Haurwitz RE, Jinek M, Wiedenheft B, Zhou K, Doudna JA (September 2010). "Sequence- and structure-specific RNA processing by a CRISPR endonuclease". Science. 329 (5997): 1355–8. Bibcode:2010Sci...329.1355H. doi:10.1126/science.1192272. PMC 3133607free to read. PMID 20829488. 
  100. ^ Carte J, Wang R, Li H, Terns RM, Terns MP (December 2008). "Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes". Genes & Development. 22 (24): 3489–96. doi:10.1101/gad.1742908. PMC 2607076free to read. PMID 19141480. 
  101. ^ Wang R, Preamplume G, Terns MP, Terns RM, Li H (February 2011). "Interaction of the Cas6 riboendonuclease with CRISPR RNAs: recognition and cleavage". Structure. 19 (2): 257–64. doi:10.1016/j.str.2010.11.014. PMC 3154685free to read. PMID 21300293. 
  102. ^ Niewoehner O, Jinek M, Doudna JA (January 2014). "Evolution of CRISPR RNA recognition and processing by Cas6 endonucleases". Nucleic Acids Research. 42 (2): 1341–53. doi:10.1093/nar/gkt922. PMC 3902920free to read. PMID 24150936. 
  103. ^ Semenova E, Jore MM, Datsenko KA, Semenova A, Westra ER, Wanner B, van der Oost J, Brouns SJ, Severinov K (June 2011). "Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence". Proceedings of the National Academy of Sciences of the United States of America. 108 (25): 10098–103. Bibcode:2011PNAS..10810098S. doi:10.1073/pnas.1104144108. PMC 3121866free to read. PMID 21646539. 
  104. ^ Gudbergsdottir S, Deng L, Chen Z, Jensen JV, Jensen LR, She Q, Garrett RA (January 2011). "Dynamic properties of the Sulfolobus CRISPR/Cas and CRISPR/Cmr systems when challenged with vector-borne viral and plasmid genes and protospacers". Molecular Microbiology. 79 (1): 35–49. doi:10.1111/j.1365-2958.2010.07452.x. PMC 3025118free to read. PMID 21166892. 
  105. ^ Manica A, Zebec Z, Teichmann D, Schleper C (April 2011). "In vivo activity of CRISPR-mediated virus defence in a hyperthermophilic archaeon". Molecular Microbiology. 80 (2): 481–91. doi:10.1111/j.1365-2958.2011.07586.x. PMID 21385233. 
  106. ^ Jore MM, Lundgren M, van Duijn E, Bultema JB, Westra ER, Waghmare SP, Wiedenheft B, Pul U, Wurm R, Wagner R, Beijer MR, Barendregt A, Zhou K, Snijders AP, Dickman MJ, Doudna JA, Boekema EJ, Heck AJ, van der Oost J, Brouns SJ (May 2011). "Structural basis for CRISPR RNA-guided DNA recognition by Cascade". Nature Structural & Molecular Biology. 18 (5): 529–36. doi:10.1038/nsmb.2019. PMID 21460843. 
  107. ^ Wiedenheft B, Lander GC, Zhou K, Jore MM, Brouns SJ, van der Oost J, Doudna JA, Nogales E (September 2011). "Structures of the RNA-guided surveillance complex from a bacterial immune system". Nature. 477 (7365): 486–9. Bibcode:2011Natur.477..486W. doi:10.1038/nature10402. PMID 21938068. 
  108. ^ Zhang J, Rouillon C, Kerou M, Reeks J, Brugger K, Graham S, Reimann J, Cannone G, Liu H, Albers SV, Naismith JH, Spagnolo L, White MF (February 2012). "Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity". Molecular Cell. 45 (3): 303–13. doi:10.1016/j.molcel.2011.12.013. PMC 3381847free to read. PMID 22227115. 
  109. ^ a b Hale CR, Zhao P, Olson S, Duff MO, Graveley BR, Wells L, Terns RM, Terns MP (November 2009). "RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex". Cell. 139 (5): 945–56. doi:10.1016/j.cell.2009.07.040. PMC 2951265free to read. PMID 19945378. 
  110. ^ a b c Marraffini LA, Sontheimer EJ (January 2010). "Self versus non-self discrimination during CRISPR RNA-directed immunity". Nature. 463 (7280): 568–71. Bibcode:2010Natur.463..568M. doi:10.1038/nature08703. PMC 2813891free to read. PMID 20072129. 
  111. ^ Touchon M, Rocha EP (2010). Randau L, ed. "The small, slow and specialized CRISPR and anti-CRISPR of Escherichia and Salmonella". PloS One. 5 (6): e11126. Bibcode:2010PLoSO...511126T. doi:10.1371/journal.pone.0011126. PMC 2886076free to read. PMID 20559554. 
  112. ^ a b c Rho M, Wu YW, Tang H, Doak TG, Ye Y (2012). "Diverse CRISPRs evolving in human microbiomes". PLoS Genetics. 8 (6): e1002441. doi:10.1371/journal.pgen.1002441. PMC 3374615free to read. PMID 22719260. 
  113. ^ a b Sun CL, Barrangou R, Thomas BC, Horvath P, Fremaux C, Banfield JF (February 2013). "Phage mutations in response to CRISPR diversification in a bacterial population". Environmental Microbiology. 15 (2): 463–70. doi:10.1111/j.1462-2920.2012.02879.x. PMID 23057534. 
  114. ^ Kuno S, Sako Y, Yoshida T (May 2014). "Diversification of CRISPR within coexisting genotypes in a natural population of the bloom-forming cyanobacterium Microcystis aeruginosa". Microbiology. 160 (Pt 5): 903–16. doi:10.1099/mic.0.073494-0. PMID 24586036. 
  115. ^ Bland C, Ramsey TL, Sabree F, Lowe M, Brown K, Kyrpides NC, Hugenholtz P (2007). "CRISPR recognition tool (CRT): a tool for automatic detection of clustered regularly interspaced palindromic repeats". BMC Bioinformatics. 8: 209. doi:10.1186/1471-2105-8-209. PMC 1924867free to read. PMID 17577412. 
  116. ^ Edgar RC (2007). "PILER-CR: fast and accurate identification of CRISPR repeats". BMC Bioinformatics. 8: 18. doi:10.1186/1471-2105-8-18. PMC 1790904free to read. PMID 17239253. 
  117. ^ Grissa I, Vergnaud G, Pourcel C (July 2007). "CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats". Nucleic Acids Research. 35 (Web Server issue): W52–7. doi:10.1093/nar/gkm360. PMC 1933234free to read. PMID 17537822. 
  118. ^ Pride DT, Salzman J, Relman DA (September 2012). "Comparisons of clustered regularly interspaced short palindromic repeats and viromes in human saliva reveal bacterial adaptations to salivary viruses". Environmental Microbiology. 14 (9): 2564–76. doi:10.1111/j.1462-2920.2012.02775.x. PMC 3424356free to read. PMID 22583485. 
  119. ^ Held NL, Herrera A, Whitaker RJ (November 2013). "Reassortment of CRISPR repeat-spacer loci in Sulfolobus islandicus". Environmental Microbiology. 15 (11): 3065–76. doi:10.1111/1462-2920.12146. PMID 23701169. 
  120. ^ Held NL, Herrera A, Cadillo-Quiroz H, Whitaker RJ (2010). "CRISPR associated diversity within a population of Sulfolobus islandicus". PloS One. 5 (9): e12988. Bibcode:2010PLoSO...512988H. doi:10.1371/journal.pone.0012988. PMC 2946923free to read. PMID 20927396. 
  121. ^ Skennerton CT, Imelfort M, Tyson GW (May 2013). "Crass: identification and reconstruction of CRISPR from unassembled metagenomic data". Nucleic Acids Research. 41 (10): e105. doi:10.1093/nar/gkt183. PMC 3664793free to read. PMID 23511966. 
  122. ^ Stern A, Mick E, Tirosh I, Sagy O, Sorek R (October 2012). "CRISPR targeting reveals a reservoir of common phages associated with the human gut microbiome". Genome Research. 22 (10): 1985–94. doi:10.1101/gr.138297.112. PMC 3460193free to read. PMID 22732228. 
  123. ^ Koonin EV, Wolf YI (2009). "Is evolution Darwinian or/and Lamarckian?". Biology Direct. 4: 42. doi:10.1186/1745-6150-4-42. PMC 2781790free to read. PMID 19906303. 
  124. ^ Weiss A (October 2015). "Lamarckian Illusions". Trends in Ecology & Evolution. 30 (10): 566–8. doi:10.1016/j.tree.2015.08.003. PMID 26411613. 
  125. ^ Heidelberg JF, Nelson WC, Schoenfeld T, Bhaya D (2009). Ahmed N, ed. "Germ warfare in a microbial mat community: CRISPRs provide insights into the co-evolution of host and viral genomes". PloS One. 4 (1): e4169. Bibcode:2009PLoSO...4.4169H. doi:10.1371/journal.pone.0004169. PMC 2612747free to read. PMID 19132092. 
  126. ^ Sampson TR, Saroj SD, Llewellyn AC, Tzeng YL, Weiss DS (May 2013). "A CRISPR/Cas system mediates bacterial innate immune evasion and virulence". Nature. 497 (7448): 254–7. Bibcode:2013Natur.497..254S. doi:10.1038/nature12048. PMC 3651764free to read. PMID 23584588. 
  127. ^ Novick RP, Christie GE, Penadés JR (August 2010). "The phage-related chromosomal islands of Gram-positive bacteria". Nature Reviews. Microbiology. 8 (8): 541–51. doi:10.1038/nrmicro2393. PMC 3522866free to read. PMID 20634809. 
  128. ^ Seed KD, Lazinski DW, Calderwood SB, Camilli A (February 2013). "A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity". Nature. 494 (7438): 489–91. Bibcode:2013Natur.494..489S. doi:10.1038/nature11927. PMC 3587790free to read. PMID 23446421. 
  129. ^ a b Ledford H (June 2015). "CRISPR, the disruptor". Nature. 522 (7554): 20–4. Bibcode:2015Natur.522...20L. doi:10.1038/522020a. PMID 26040877. 
  130. ^ "CRISPR/Cas9 Plasmids". www.systembio.com. Retrieved 2015-12-17. 
  131. ^ "CRISPR Cas9 Genome Editing". www.origene.com. OriGene. Retrieved 2015-12-17. 
  132. ^ a b c d Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (November 2013). "Genome engineering using the CRISPR-Cas9 system". Nature Protocols. 8 (11): 2281–308. doi:10.1038/nprot.2013.143. PMC 3969860free to read. PMID 24157548. 
  133. ^ Horvath P, Barrangou R (January 2010). "CRISPR/Cas, the immune system of bacteria and archaea". Science. 327 (5962): 167–70. doi:10.1126/science.1179555. PMID 20056882. 
  134. ^ Bialk P, Rivera-Torres N, Strouse B, Kmiec EB (2015-06-08). "Regulation of Gene Editing Activity Directed by Single-Stranded Oligonucleotides and CRISPR/Cas9 Systems". PloS One. 10 (6): e0129308. doi:10.1371/journal.pone.0129308. PMC 4459703free to read. PMID 26053390. 
  135. ^ "Optimized CRISPR Design". crispr.mit.edu. Retrieved 2015-12-20. 
  136. ^ "Scientists successfully edit human immune-system T cells | KurzweilAI". www.kurzweilai.net. Retrieved 2016-01-01. 
  137. ^ Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A (August 2015). "Generation of knock-in primary human T cells using Cas9 ribonucleoproteins". Proceedings of the National Academy of Sciences of the United States of America. 112 (33): 10437–42. doi:10.1073/pnas.1512503112. PMC 4547290free to read. PMID 26216948. 
  138. ^ Zimmerman C (Oct 15, 2015). "Editing of Pig DNA May Lead to More Organs for People". NY Times. 
  139. ^ Hale CR, Majumdar S, Elmore J, Pfister N, Compton M, Olson S, Resch AM, Glover CV, Graveley BR, Terns RM, Terns MP (February 2012). "Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs". Molecular Cell. 45 (3): 292–302. doi:10.1016/j.molcel.2011.10.023. PMC 3278580free to read. PMID 22227116. 
  140. ^ Sorek R, Kunin V, Hugenholtz P (March 2008). "CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea". Nature Reviews. Microbiology. 6 (3): 181–6. doi:10.1038/nrmicro1793. PMID 18157154. 
  141. ^ Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (February 2013). "Multiplex genome engineering using CRISPR/Cas systems". Science. 339 (6121): 819–23. Bibcode:2013Sci...339..819C. doi:10.1126/science.1231143. PMC 3795411free to read. PMID 23287718. 
  142. ^ Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (February 2013). "RNA-guided human genome engineering via Cas9". Science. 339 (6121): 823–6. Bibcode:2013Sci...339..823M. doi:10.1126/science.1232033. PMC 3712628free to read. PMID 23287722. 
    Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, Thomson JA (September 2013). "Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis". Proceedings of the National Academy of Sciences of the United States of America. 110 (39): 15644–9. Bibcode:2013PNAS..11015644H. doi:10.1073/pnas.1313587110. 
  143. ^ a b c d e f Science News Staff (December 17, 2015). "And Science's Breakthrough of the Year is ...". news.sciencemag.org. Retrieved 2015-12-21. 
  144. ^ Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (January 2014). "Genome-scale CRISPR-Cas9 knockout screening in human cells". Science. 343 (6166): 84–7. doi:10.1126/science.1247005. PMC 4089965free to read. PMID 24336571. 
  145. ^ a b Zimmer C (2016-06-03). "Scientists Find Form of Crispr Gene Editing With New Capabilities". The New York Times. ISSN 0362-4331. Retrieved 2016-06-10. 
  146. ^ van Erp PB, Bloomer G, Wilkinson R, Wiedenheft B (June 2015). "The history and market impact of CRISPR RNA-guided nucleases". Current Opinion in Virology. 12: 85–90. doi:10.1016/j.coviro.2015.03.011. PMID 25914022. 
  147. ^ Maggio I, Gonçalves MA (May 2015). "Genome editing at the crossroads of delivery, specificity, and fidelity". Trends in Biotechnology. 33 (5): 280–91. doi:10.1016/j.tibtech.2015.02.011. PMID 25819765. 
  148. ^ Rath D, Amlinger L, Rath A, Lundgren M (October 2015). "The CRISPR-Cas immune system: biology, mechanisms and applications". Biochimie. 117: 119–28. doi:10.1016/j.biochi.2015.03.025. PMID 25868999. 
  149. ^ a b Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, Saad AF, Li MK, Hughes MR, Werff RV, Peters DT, Lu J, Baccei A, Siedlecki AM, Valerius MT, Musunuru K, McNagny KM, Steinman TI, Zhou J, Lerou PH, Bonventre JV (23 October 2015). "Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids". Nature Communications. 6: 8715. doi:10.1038/ncomms9715. PMID 26493500. 
  150. ^ Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, Tertoolen LG, Jung CB, Elliott DA, Welling A, Laugwitz KL, Moretti A, Mummery CL (December 2013). "Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome". The EMBO Journal. 32 (24): 3161–75. doi:10.1038/emboj.2013.240. PMC 3981141free to read. PMID 24213244. 
  151. ^ Citorik RJ, Mimee M, Lu TK (November 2014). "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases". Nature Biotechnology. 32 (11): 1141–5. doi:10.1038/nbt.3011. PMC 4237163free to read. PMID 25240928. 
  152. ^ van Diemen, FR; et al. "Using CRISPR to combat viral infections: a new way to treat herpes?". PLOS Media YouTube Channel. PLOS.org. Retrieved 4 August 2016. 
  153. ^ Abrahimi P, Chang WG, Kluger MS, Qyang Y, Tellides G, Saltzman WM, Pober JS (July 2015). "Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9". Circulation Research. 117 (2): 121–8. doi:10.1161/CIRCRESAHA.117.306290. PMID 25940550. 
  154. ^ Yong E (2015-11-25). "The Revolutionary Gene-Editing Technique That Reveals Cancer's Weaknesses". The Atlantic. Retrieved 2016-02-21. 
  155. ^ Gu W, Crawford ED, O'Donovan BD, Wilson MR, Chow ED, Retallack H, DeRisi JL (2016). "Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications". Genome Biology. 17: 41. doi:10.1186/s13059-016-0904-5. PMC 4778327free to read. PMID 26944702. 
  156. ^ "Who Owns the Biggest Biotech Discovery of the Century? There's a bitter fight over the patents for CRISPR, a breakthrough new form of DNA editing.". MIT Technology Review. Retrieved 25 February 2015. CRISPR Patents Spark Fight to Control Genome Editing 
  157. ^ Fye S. "Genetic Rough Draft: Editas and CRISPR". The Atlas Business Journal. Retrieved 19 January 2016. 
  158. ^ "CRISPR Madness". GEN. 
  159. ^ Staff (1 April 2015). "News: Products & Services". Genetic Engineering & Biotechnology News (Paper). 35 (7): 8. 
  160. ^ Antonio Regalado for MIT Technology Review, March 5, 2015 Engineering the Perfect Baby
  161. ^ Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (March 2015). "Don't edit the human germ line". Nature. 519 (7544): 410–1. Bibcode:2015Natur.519..410L. doi:10.1038/519410a. PMID 25810189. 
  162. ^ Wade N (19 March 2015). "Scientists Seek Ban on Method of Editing the Human Genome". The New York Times. Retrieved 20 March 2015. The biologists writing in Science support continuing laboratory research with the technique, and few if any scientists believe it is ready for clinical use. 
  163. ^ Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J (May 2015). "CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes". Protein & Cell. 6 (5): 363–72. doi:10.1007/s13238-015-0153-5. PMC 4417674free to read. PMID 25894090. 
  164. ^ Kolata G (23 April 2015). "Chinese Scientists Edit Genes of Human Embryos, Raising Concerns". The New York Times. Retrieved 24 April 2015. 
  165. ^ a b "Chinese scientists genetically modify human embryos". Nature. 22 April 2015. 
  166. ^ Regalado, Antonio (2016-05-08). "Chinese Researchers Experiment with Making HIV-Proof Embryos". MIT Technology Review. Retrieved 2016-06-10. 
  167. ^ "International Summit on Gene Editing". National Academies of Sciences, Engineering, and Medicine. 3 December 2015. Retrieved 3 December 2015. 
  168. ^ Gallagher J (1 February 2016). "Scientists get 'gene editing' go-ahead". BBC News. BBC. Retrieved 1 February 2016. 
  169. ^ Cheng M (1 February 2016). "Britain approves controversial gene-editing technique". AP News. Retrieved 1 February 2016. 
  170. ^ Talbot D (2016). "Precise Gene Editing in Plants/ 10 Breakthrough Technologies 2016". Massachusetts Institute of Technology. Retrieved 18 March 2016. 
  171. ^ Larson C, Schaffer A (2014). "Genome Editing/ 10 Breakthrough Technologies 2014". Massachusetts Institute of Technology. Retrieved 18 March 2016. 

Further reading[edit]